Fierce Health Payers January 28, 2020
Robert King

Editor’s note: A previous version of this story incorrectly identified who receives the drug discounts.

The federal government isn’t doing a good job of determining whether a drug company has to provide both 340B discounts and rebates for Medicaid, a federal watchdog said.

The Government Accountability Office (GAO) said in a report Tuesday (PDF) that the Centers for Medicare & Medicaid Services (CMS) only provides limited oversight of state efforts to quash duplicate discounts. Audits from the Health Resources and Services Administration (HRSA) are also lacking, the report found.

A safety net hospital can qualify to get a 25% to 50% discount for drug products under 340B, but those facilities are not eligible for drug rebates from Medicaid. A...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: GAO, Govt Agencies, Insurance, Market Research, Medicaid, Pharma, States, Trends
Navigating the Shift: 2026 Medicare Drug Pricing and the Future of Pharmacy
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety

Share Article